Patient with non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Part 2. Secondary prophylaxis ; Пациент с некардиоэмболическим ишемическим инсультом или транзиторной ишемической атакой высокого риска. Часть 2. Вторичная профилактика

Συγγραφείς: A. A. Kulesh, S. N. Yanishevsky, D. A. Demin, L. I. Syromyatnikova, O. I. Vinogradov, А. А. Кулеш, С. Н. Янишевский, Д. А. Демин, Л. И. Сыромятникова, О. И. Виноградов

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 3 (2023); 4-10 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 3 (2023); 4-10 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-3

Θεματικοί όροι: комбинированная антитромботическая терапия, atherothrombotic stroke, transient ischemic attack, secondary prevention, combined antithrombotic therapy, атеротромботический инсульт, транзиторная ишемическая атака, вторичная профилактика

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2022/1528; Кулеш АА, Янишевский СН, Демин ДА и др. Пациент с некардиоэмболическим ишемическим инсультом или транзиторной ишемической атакой высокого риска. Часть 1. Диагностика. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):10-8. doi:10.14412/2074-27112023-2-10-18; Wang Y, Wang Y, Zhao X, et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi:10.1056/NEJMoa1215340; Johnston SC, Easton JD, Farrant M, et al. Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19;379(3):215-25. doi:10.1056/NEJMoa1800410; Johnston SC, Amarenco P, Denison H, et al. THALES Investigators. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020 Jul 16;383(3):207-17. doi:10.1056/NEJMoa1916870; Krishnan K, Law ZK, Minhas JS, et al. Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician. Clin Med (Lond). 2022 Sep;22(5):449-54. doi:10.7861/clinmed.20210597; Pan Y, Elm JJ, Li H, et al. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol. 2019 Dec 1;76(12):1466-73. doi:10.1001/jamaneurol.2019.2531; Amarenco P, Denison H, Evans SR, et al. THALES Steering Committee and Investigators*. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke. 2020 Dec;51(12):3504-13. doi:10.1161/STROKEAHA.120.032239; Wang Y, Pan Y, Li H, et al. Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology. 2022 Jul 5;99(1):e46-e54. doi:10.1212/WNL.0000000000200355; Dawson J, Merwick A, Webb A, et al. European Stroke Organisation. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Eur Stroke J. 2021 Jun;6(2):VI. doi:10.1177/23969873211027006; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375; Amin HP, Madsen TE, Bravata DM, et al. American Heart Association Emergency Neurovascular Care Committee of the Stroke Council and Council on Peripheral Vascular Disease. Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting: A Scientific Statement from the American Heart Association. Stroke. 2023 Mar;54(3):e109-e121. doi:10.1161/STR.0000000000000418. Epub 2023 Jan 19.; Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-30. doi:10.1056/NEJMoa1709118; Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019 Feb 26;139(9):1134-45. doi:10.1161/CIRCULATIONAHA.118.035864; Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021 Oct 14;42(39):4013-24. doi:10.1093/eurheartj/ehab390; Dawson J, Bejot Y, Christensen LM, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022 Sep;7(3):I-II. doi:10.1177/23969873221100032; Арутюнов ГП, Амелин АВ, Вознюк ИА и др. Значение результатов исследования COMPASS в изменении подходов к лечению пациентов неврологического профиля. Заключение совета экспертов от 18 декабря 2021 г. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(4):1-6. doi:10.17116/jnevro202212204194; Psychogios M, Brehm A, Lopez-Cancio E, et al. European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease. Eur Stroke J. 2022 Sep;7(3):III-IV. doi:10.1177/23969873221099715; Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014 Jan 25;383(9914):333-41. doi:10.1016/S01406736(13)62038-3; Ntaios G, Pearce LA, Meseguer E, et al. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke. 2019 Nov;50(11):3184-90. doi:10.1161/STROKEAHA.119.025813; Hawkes MA, Braksick SA, Zhang W, et al. Can we stop the stuttering in stroke? Interventions in 40 patients with acute lacunes. J Neurol Sci. 2019 Jun 15;401:1-4. doi:10.1016/j.jns.2019.04.009; Berberich A, Schneider C, Reiff T, et al. Dual Antiplatelet Therapy Improves Functional Outcome in Patients With Progressive Lacunar Strokes. Stroke. 2019 Apr;50(4):1007-9. doi:10.1161/STROKEAHA.118.023789; Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009 May;8(5):453-63. doi:10.1016/S14744422(09)70058-4; Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-37. doi:10.1093/eurheartj/ehab484; Zeitouni M, Sabouret P, Kerneis M, et al. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):324-33. doi:10.1093/ehjcvp/pvaa077; Вознюк ИА, Шамалов НА, Ежов МВ и др. Оптимизация гиполипидемической терапии у пациентов, перенесших ишемический инсульт. Резолюция Совета экспертов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(6):152-61. doi:10.17116/jnevro2020120061152; Кухарчук ВВ, Ежов МВ, Сергиенко ИВ и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002; Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021 May;325:99-109. doi:10.1016/j.atherosclerosis.2021.03.039; Giugliano RP, Pedersen TR, Saver JL, et al. FOURIER Investigators. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020 May;51(5):1546-54. doi:10.1161/STROKEAHA.119.027759; Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020 Nov1;134:69-73. doi:10.1016/j.amjcard.2020.08.018; Hsu C, Saver JL, Ovbiagele B, et al. Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention: A Meta-analysis and Meta-Regression. JAMA Neurol. 2023 May 1;80(5):506-15. doi:10.1001/jamaneurol.2023.0218; Dolui S, Detre JA, Gaussoin SA, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. JAMA Neurol. 2022 Apr 1;79(4):380-9. doi:10.1001/jamaneurol.2022.0074; SPRINT MIND Investigators for the SPRINT Research Group; Nasrallah IM, Pajewski NM, Auchus AP, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA. 2019 Aug 13;322(6):524-34. doi:10.1001/jama.2019.10551; Nasrallah IM, Gaussoin SA, Pomponio R, et al. SPRINT Research Group. Association of Intensive vs Standard Blood Pressure Control with Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial. JAMA Neurol. 2021 May 1;78(5):568-77. doi:10.1001/jamaneurol.2021.0178; Paciaroni M, Agnelli G, Caso V, et al. Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. Cerebrovasc Dis. 2009;28(2):119-23. doi:10.1159/000223436. Epub 2009 Jun 5.; Staszewski J, Brodacki B, Kotowicz J, Stepien A. Intravenous insulin therapy in the maintenance of strict glycemic control in nondiabetic acute stroke patients with mild hyperglycemia. J Stroke Cerebrovasc Dis. 2011 Mar-Apr;20(2):150-4. doi:10.1016/j.jstrokecerebrovasdis.2009.11.013. Epub 2010 Jul 10.; Rosso C, Corvol JC, Pires C, et al. Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial. Stroke. 2012 Sep;43(9):2343-9. doi:10.1161/STROKEAHA.112.657122. Epub 2012 Jun 14.; Johnston KC, Bruno A, Pauls Q, et al. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019 Jul 23;322(4):326-35. doi:10.1001/jama.2019.9346; Shou J, Zhou L, Zhu S, Zhang X. Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis. 2015;24:1961-8. doi:10.1016/j.jstrokecerebrovasdis.2015.04.004; Cosentino F, Grant PJ, Aboyans V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi:10.1093/eurheartj/ehz486; American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. doi:10.2337/dc22S009; Joseph JJ, Deedwania P, Acharya T, et al. American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022 Mar;145(9):e722e759. doi:10.1161/CIR.0000000000001040; Naylor R, Rantner B, Ancetti S, et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2022 May 20:S1078-5884(22)00237-4. doi:10.1016/j.ejvs.2022.04.011; Bonati LH, Kakkos S, Berkefeld J, et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. Eur Stroke J. 2021 Jun;6(2):IXLVII. doi:10.1177/23969873211012121; Eriksson H, Koskinen S, Nuotio K, et al. Predictive Factors for Pre-operative Recurrence of Cerebrovascular Symptoms in Symptomatic Carotid Stenosis. Eur J Vasc Endovasc Surg. 2020 Dec;60(6):809-15. doi:10.1016/j.ejvs.2020.08.044; Cui CL, Dakour-Aridi H, Lu JJ, et al. In-Hospital Outcomes of Urgent, Early, or Late Revascularization for Symptomatic Carotid Artery Stenosis. Stroke. 2022 Jan;53(1):100-7. doi:10.1161/STROKEAHA.120.032410; Чернявский МА, Иртюга ОБ, Янишевский СН и др. Российский консенсус по диагностике и лечению пациентов со стенозом сонных артерий. Российский кардиологический журнал. 2022;27(11):5284. doi:10.15829/1560-4071-2022-5284; Gao P, Wang T, Wang D, et al. CASSISS Trial Investigators. Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial. JAMA. 2022 Aug 9;328(6):534-42. doi:10.1001/jama.2022.12000; Turan TN, Zaidat OO, Gronseth GS, et al. Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee. Neurology. 2022 Mar 22;98(12):486-98. doi:10.1212/WNL.0000000000200030

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/2022
https://doi.org/10.14412/2074-2711-2023-3-4-10

STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION ; СТРАТЕГИЯ МИНИМИЗАЦИИ РИСКОВ КРОВОТЕЧЕНИЙ У БОЛЬНЫХ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ, ПОЛУЧАЮЩИХ КОМБИНИРОВАННУЮ АНТИТРОМБОТИЧЕСКУЮ ТЕРАПИЮ ПОСЛЕ ЧРЕСКОЖНОГО КОРОНАРНОГО ВМЕШАТЕЛЬСТВА

Συγγραφείς: D. A. Zateishchikov, Д. А. Затейщиков

Πηγή: Aterotromboz = Atherothrombosis; № 1 (2018); 33-42 ; Атеротромбоз; № 1 (2018); 33-42 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2018-1

Θεματικοί όροι: апиксабан, percutaneous coronary intervention, combined antithrombotic therapy, bleeding risk, dabigatran, rivaroxaban, apixaban, чрескожное коронарное вмешательство, комбинированная антитромботическая терапия, риск кровотечений, дабигатран, ривароксабан

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/148/180; Valgimigli M et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018, 39 (3): 213–260.; Costa F et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individualpatient datasets from clinical trials. The Lancet, 2017, 389 (10073): 1025–1034.; Thygesen K et al. Third universal definition of myocardial infarction. Circulation, 2012, 126 (16): 2020–35.; Mehran R et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv, 2011, 4 (6): 654–664.; A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med, 1998, 338 (21): 1498–505.; Cannon CP et al. Oral glycoprotein IIb / IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation, 2000, 102 (2): 149–156.; Mahaffey KW et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 2011, 124 (5): 544–554.; Singh M. Bleeding Avoidance Strategies During Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2015, 65 (20): 2225–2238.; Subherwal S et al. Baseline Risk of Major Bleeding in Non – ST-Segment – Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC / AHA guidelines) Bleeding Score. Circulation, 2009, 119 (14): 1873–1882.; Mathews R et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry (R) – GWTG. Am J Cardiol, 2011, 107 (8): 1136–1143.; O’Brien EC et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal, 2015, 36 (46): 3258–3264.; Hijazi Z et al. The novel biomarker-based ABC (age, biomarkers, clinical history) – bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, 2016, 387 (10035): 2302–2311.; Dewilde WJM et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet, 2013, 381 (9872): 1107–1115.; Gibson CM et al. Prevention of Bleeding in Patient s with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375 (25): 2423–2434.; Cannon CP et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med, 2017, 377 (16): 1513–1524.; Steffel J et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist or al anticoagulants in patients with atrial fibrillation. Eur Heart J, 2018: ehy136-ehy136.; Eikelboom JW et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia, 2018, 120 (4): 645–656.; Pollack CV Jr et al. Idarucizumab for Dabigatr an Reversal – Full Cohort Analysis. N Engl J Med, 2017, 377 (5): 431–441.; https://www.aterotromboz.ru/jour/article/view/148

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/148
https://doi.org/10.21518/2307-1109-2018-1-33-42

Современные тенденции диагностики и лечения острых коронарных синдромов на догоспитальном этапе скорой медицинской помощи ; Modern tendencies of diagnostics and treatment of acute coronary syndromes on the stage of medical first-aid

Συγγραφείς: Ostroumova, L. A., Yarkov, I. V., Brajin, A. V., Остроумова, Л. А., Ярков, И. В., Бражин, А. В.

Θεματικοί όροι: ACUTE CORONARY SYNDROMES, PRE-HOSPITAL THROMBOLYSIS, MARKERS OF MYOCARDIAL NECROSIS, ANTIPLATELET СО-THERAPY, ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ, ДОГОСПИТАЛЬНЫЙ ТРОМБОЛИЗИС, БИОМАРКЕРЫ НЕКРОЗА МИОКАРДА, КОМБИНИРОВАННАЯ АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ

Περιγραφή αρχείου: application/pdf

Relation: Уральский медицинский журнал. 2009. Т. 63, № 9.; http://elib.usma.ru/handle/usma/16674

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/16674

ЕВРОПЕЙСКИЕ РЕКОМЕНДАЦИИ ПО ВЕДЕНИЮ ПАЦИЕНТОВ С ХРОНИЧЕСКИМИ КОРОНАРНЫМИ СИНДРОМАМИ 2019 Г.: В ФОКУСЕ НОВОЕ НАПРАВЛЕНИЕ ПРОФИЛАКТИКИ СОБЫТИЙ

Θεματικοί όροι: КОМБИНИРОВАННАЯ АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ, MULTIFOCAL ATHEROSCLEROSIS, СТАБИЛЬНАЯ ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА, COMBINED ANTIPLATELET THERAPY, STABLE CORONARY HEART DISEASE, МУЛЬТИФОКАЛЬНОЕ АТЕРОСКЛЕРОТИЧЕСКОЕ ПОРАЖЕНИЕ, ХРОНИЧЕСКИЕ КОРОНАРНЫЕ СИНДРОМЫ, НИЗКИЕ ДОЗЫ РИВАРОКСАБАНА, CHRONIC CORONARY SYNDROMES, LOW DOSES OF RIVAROXABAN